Breyanzi genetically modified autologous T cells Images
Generic Name: lisocabtagene maraleucel
This medication has been identified as Breyanzi genetically modified autologous T cells and is used for Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, and Mantle Cell Lymphoma. It belongs to the drug class miscellaneous antineoplastics and is not a controlled substance.
Images of medication
Breyanzi
- Generic Name
- lisocabtagene maraleucel
- Strength
- genetically modified autologous T cells
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Bristol-Myers Squibb Company
- National Drug Code (NDC)
- 73153-0900
See also:
More about Breyanzi (lisocabtagene maraleucel)
- Check interactions
- Compare alternatives
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.